Research programme: G protein-coupled receptor modulators - Kainova Therapeutics/XOMA
Latest Information Update: 22 Jan 2026
At a glance
- Originator Domain Therapeutics; XOMA
- Developer Kainova Therapeutics; XOMA
- Class Antibodies
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified